In a specific clinical trial involving treatment-naive NSCLC patients with advanced EGFR mutations, the combined use of apatinib (an oral angiogenesis inhibitor targeting VEGFR2) and gefitinib as a first-line treatment has been found to improve progression-free survival (PFS) [12]. The gene discussed is KDR; the disease is non-small cell lung carcinoma.